Devita, Hellman, and Rosenberg's Cancer

LWBK1006-08 LWW-Govindan-Review December 12, 2011 18:49

96 DeVita, Hellman, and Rosenberg’s CANCER: Principles and Practice of Oncology Review

Question 8.5. The goals of therapy in incurable, advanced, metastatic disease include

all of the following, EXCEPT:

A. Palliate tumor-related symptoms

B. Eradicate all evidence of cancer

C. Improve quality of life

D. Prolong time to tumor progression

Question 8.6. Neoadjuvant chemotherapy can be utilized in all of the following cancers

EXCEPT:

A. Head and neck cancer

B. Non-small cell lung cancer

C. Hematologic malignancies

D. Pancreatic cancer

Question 8.7. All of the following are true concerning the role of adjuvant chemother-

apy, EXCEPT:

A. Risk reduction in local recurrence

B. Risk reduction in distant recurrence

C. Primary therapy instead of surgery and/or radiation

D. Prolongation of disease-free and overall survival in osteogenic sar-

coma

Question 8.8. Apoptosis is inhibited by the activation of the following EXCEPT:

A. Bcl-2

B. NF-B

C. Caspases

D. Bcl-xL

Question 8.9. The most important indicator of the effectiveness of chemotherapy is:

A. Achievement of a minor response

B. Achievement of a partial response

C. Achievement of a complete response

D. Achievement of stable disease

Question 8.10. A partial response is defined as:

A. At least a 50% reduction in measurable tumor mass

B. At least a 10% reduction in measurable tumor mass

C. Improvement in quality of life

D. Improvement in survival

Question 8.11. Anticancer activity of bortezomib is due to the inhibition of:

A. Proteasome

B. Bcl-2

C. Thymidylate synthase

D. MDM2